INCY: second_quarter 2026 lobbying report

{"url":"https://lda.gov/api/v1/filings/68e708e5-1879-47a9-88ed-802a26d20e2b/","filing_uuid":"68e708e5-1879-47a9-88ed-802a26d20e2b","filing_type":"2T","filing_type_display":"2nd Quarter - Termination","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/68e708e5-1879-47a9-88ed-802a26d20e2b/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-19T07:28:53-04:00","termination_date":"2026-06-30","registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2231 48th Street NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20007","registrant":{"id":401108183,"url":"https://lda.gov/api/v1/registrants/401108183/","house_registrant_id":56368,"name":"LMH STRATEGIC SOLUTIONS","description":null,"address_1":"2231 48th Street NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20007","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ALANNA TEMME","contact_telephone":"+1 202-503-5189","dt_updated":"2026-07-09T12:14:41.865548-04:00"},"client":{"id":67833,"url":"https://lda.gov/api/v1/clients/67833/","client_id":67833,"name":"INCYTE CORPORATION","general_description":"Biopharmaceutical Company","client_government_entity":null,"client_self_select":false,"state":"DE","state_display":"Delaware","country":"US","country_display":"United States of America","ppb_state":"DE","ppb_state_display":"Delaware","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-07-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145804,"prefix":null,"prefix_display":null,"first_name":"ALANNA","nickname":null,"middle_name":null,"last_name":"TEMME","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145804,"prefix":null,"prefix_display":null,"first_name":"ALANNA","nickname":null,"middle_name":null,"last_name":"TEMME","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}